• Panacea initiates Phase I prostate cancer vaccine therapy trial europeanpharmaceuticalreview
    January 20, 2017
    Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity.
PharmaSources Customer Service